Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study von Ott, Patrick A, Bang, Yung-Jue, Berton-Rigaud, Dominique, Elez, Elena, Pishvaian, Michael J, Rugo, Hope S, Puzanov, Igor, Mehnert, Janice M, Aung, Kyaw L, Lopez, Juanita, Carrigan, Marion, Saraf, Sanatan, Chen, Mei, Soria, Jean-Charles

Volltext

Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study von Ott, Patrick A, Bang, Yung-Jue, Berton-Rigaud, Dominique, Elez, Elena, Pishvaian, Michael J, Rugo, Hope S, Puzanov, Igor, Mehnert, Janice M, Aung, Kyaw L, Lopez, Juanita, Carrigan, Marion, Saraf, Sanatan, Chen, Mei, Soria, Jean-Charles

Volltext

Pembrolizumab in advanced endometrial cancer: Preliminary results from the phase Ib KEYNOTE-028 study von Ott, Patrick Alexander, Bang, Yung-Jue, Berton-Rigaud, Dominique, Elez, Elena, Pishvaian, Michael J., Rugo, Hope S., Puzanov, Igor, Morgan, Mark Aloysuis, Mehnert, Janice M., Aung, Kyaw Lwin, Carrigan, Marion, Saraf, Sanatan, Chen, Mei, Soria, Jean-Charles

Volltext

A Phase 1, Open-Label, Multi-Center, Multiple-Dose, Dose-Escalation Study of MDX-1342 in Patients with CD19-Positive Refractory/Relapsed Chronic Lymphocytic Leukemia von Camacho, Luis H, Joyce, Robin, Brown, Jennifer R, Chanan-Khan, Asher, Amrein, Philip C., Assad, Albert, Carrigan, Marion

Volltext